Literature DB >> 21193989

The slow cell death response when screening chemotherapeutic agents.

Joseph Blois1, Adam Smith, Lee Josephson.   

Abstract

PURPOSE: To examine the correlation between cell death and a common surrogate of death used in screening assays, we compared cell death responses to those obtained with the sulforhodamine B (SRB) cell protein-based "cytotoxicity" assay.
METHOD: With the SRB assay, the Hill equation was used to obtain an IC50 and final cell mass, or cell mass present at infinite agent concentrations, with eight adherent cell lines and four agents (32 agent/cell combinations). Cells were treated with high agent concentrations (well above the SRB IC50) and the death response determined as the time-dependent decrease in cells failing to bind both annexin V and vital fluorochromes by flow cytometry.
RESULTS: Death kinetics were categorized as fast (5/32) (similar to the reference nonadherent Jurkat line), slow (17/32), or none (10/32), despite positive responses in the SRB assay in all cases. With slow cell death, a single exposure to a chemotherapeutic agent caused a slow, progressive increase in dead (necrotic) and dying (apoptotic) cells for at least 72 h.
CONCLUSIONS: Cell death (defined by annexin and/or fluorochrome binding) did not correlate with the standard SRB "cytotoxicity" assay. With the slow cell death response, a single exposure to an agent caused a slow conversion from vital to apoptotic and necrotic cells over at least 72 h (the longest time point examined). Here, increasing the time of exposure to agent concentrations modestly above the SRB IC50 provides a method of maximizing cell kill. If tumors respond similarly, sustained low doses of chemotherapeutic agents, rather than a log-kill, maximum tolerated dose strategy may be an optimal strategy of maximizing tumor cell death.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21193989      PMCID: PMC3210817          DOI: 10.1007/s00280-010-1549-9

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  20 in total

1.  Growth of endothelial and HeLa cells on a new multipurpose microcarrier that is positive, negative or collagen coated.

Authors:  B S Jacobson; U S Ryan
Journal:  Tissue Cell       Date:  1982       Impact factor: 2.466

2.  A DNA-binding Gd chelate for the detection of cell death by MRI.

Authors:  Elisabeth Garanger; Scott A Hilderbrand; Joseph T Blois; David E Sosnovik; Ralph Weissleder; Lee Josephson
Journal:  Chem Commun (Camb)       Date:  2009-06-12       Impact factor: 6.222

3.  Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines.

Authors:  L V Rubinstein; R H Shoemaker; K D Paull; R M Simon; S Tosini; P Skehan; D A Scudiero; A Monks; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

4.  A novel in vitro chemosensitivity test using materials collected by endoscopic biopsy.

Authors:  T Hirai; K Kawano; N Hirabayashi; M Nishiyama; Y Yamashita; H Mukaida; T Iwata; T Toge
Journal:  Anticancer Drugs       Date:  1991-06       Impact factor: 2.248

5.  From the Gla domain to a novel small-molecule detector of apoptosis.

Authors:  Avi Cohen; Anat Shirvan; Galit Levin; Hagit Grimberg; Ayelet Reshef; Ilan Ziv
Journal:  Cell Res       Date:  2009-05       Impact factor: 25.617

6.  Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma.

Authors:  P E Andreotti; I A Cree; C M Kurbacher; D M Hartmann; D Linder; G Harel; I Gleiberman; P A Caruso; S H Ricks; M Untch
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

7.  Imaging the molecular signatures of apoptosis and injury with radiolabeled annexin V.

Authors:  Francis G Blankenberg
Journal:  Proc Am Thorac Soc       Date:  2009-08-15

8.  Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide.

Authors:  Quang-Dé Nguyen; Graham Smith; Matthias Glaser; Meg Perumal; Erik Arstad; Eric O Aboagye
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-03       Impact factor: 11.205

9.  Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing.

Authors:  Y P Keepers; P E Pizao; G J Peters; J van Ark-Otte; B Winograd; H M Pinedo
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

10.  Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009.

Authors:  G Kroemer; L Galluzzi; P Vandenabeele; J Abrams; E S Alnemri; E H Baehrecke; M V Blagosklonny; W S El-Deiry; P Golstein; D R Green; M Hengartner; R A Knight; S Kumar; S A Lipton; W Malorni; G Nuñez; M E Peter; J Tschopp; J Yuan; M Piacentini; B Zhivotovsky; G Melino
Journal:  Cell Death Differ       Date:  2008-10-10       Impact factor: 15.828

View more
  6 in total

Review 1.  PEG-b-PLA micelles and PLGA-b-PEG-b-PLGA sol-gels for drug delivery.

Authors:  Hyunah Cho; Jieming Gao; Glen S Kwon
Journal:  J Control Release       Date:  2015-12-15       Impact factor: 9.776

2.  Cytoprotective nanoparticles by conjugation of a polyhis tagged annexin V to a nanoparticle drug.

Authors:  Howard H Chen; Hushan Yuan; Hoonsung Cho; David E Sosnovik; Lee Josephson
Journal:  Nanoscale       Date:  2015-02-14       Impact factor: 7.790

3.  Cytotoxic effect of Efavirenz in BxPC-3 pancreatic cancer cells is based on oxidative stress and is synergistic with ionizing radiation.

Authors:  Markus Hecht; Thomas Harrer; Verena Körber; Eric O Sarpong; Fabian Moser; Nora Fiebig; Manuela Schwegler; Michael Stürzl; Rainer Fietkau; Luitpold V Distel
Journal:  Oncol Lett       Date:  2017-12-05       Impact factor: 2.967

4.  Negative Modulation of Macroautophagy by Stabilized HERPUD1 is Counteracted by an Increased ER-Lysosomal Network With Impact in Drug-Induced Stress Cell Survival.

Authors:  Gabriela Vargas; Omar Cortés; Eloisa Arias-Muñoz; Sergio Hernández; Cristobal Cerda-Troncoso; Laura Hernández; Alexis E González; Michael H Tatham; Hianara A Bustamante; Claudio Retamal; Jorge Cancino; Manuel Varas-Godoy; Ronald T Hay; Alejandro Rojas-Fernández; Viviana A Cavieres; Patricia V Burgos
Journal:  Front Cell Dev Biol       Date:  2022-03-02

5.  A comparative analysis of in vitro toxicity of diesel exhaust particles from combustion of 1st- and 2nd-generation biodiesel fuels in relation to their physicochemical properties-the FuelHealth project.

Authors:  Anna Lankoff; Kamil Brzoska; Joanna Czarnocka; Magdalena Kowalska; Halina Lisowska; Remigiusz Mruk; Johan Øvrevik; Aneta Wegierek-Ciuk; Mariusz Zuberek; Marcin Kruszewski
Journal:  Environ Sci Pollut Res Int       Date:  2017-07-03       Impact factor: 4.223

6.  Therapeutic Effect of Repurposed Temsirolimus in Lung Adenocarcinoma Model.

Authors:  Hsuen-Wen Chang; Min-Ju Wu; Zih-Miao Lin; Chueh-Yi Wang; Shu-Yun Cheng; Yen-Kuang Lin; Yen-Hung Chow; Hui-Ju Ch'ang; Vincent H S Chang
Journal:  Front Pharmacol       Date:  2018-07-24       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.